Pivotal Role of Cranial Irradiation-Induced Peripheral, Intrinsic, and Brain-Engrafting Macrophages in Malignant Glioma [0.03%]
颅脑放疗诱导的外周、固有和脑嵌入小胶质细胞/巨噬细胞在恶性胶质瘤中的关键作用
Seidu A Richard,Sagor Kumar Roy,Emmanuel Akomanin Asiamah
Seidu A Richard
Malignant (high-grade) gliomas are aggressive intrinsic brain tumors that diffusely infiltrate the brain parenchyma. They comprise of World Health Organization (WHO) grade III and IV gliomas. Ionizing radiation or irradiation (IR) is freque...
Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non-Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study [0.03%]
关于酪氨酸激酶抑制剂在卡塔尔转移性非小细胞肺癌患者中使用情况的描述分析：全国队列研究的真实世界数据
Rawan Dawoud,Harman Saman,Kakil Rasul et al.
Rawan Dawoud et al.
Background: There has been significant improvement in treating metastatic non-small-cell lung cancer (mNSCLC) over the past 2 decades. The aim of this study is to describe the use of tyrosine kinase inhibitors (TKIs) in Q...
Unraveling the Mechanism of Action of Ubiquitin-Specific Protease 5 and Its Inhibitors in Tumors [0.03%]
泛素特异性蛋白酶5及其在肿瘤中的抑制剂的作用机制研究
Jie Wang,Shizhen Fang,Yang Jiang et al.
Jie Wang et al.
Ubiquitin-specific protease 5 (USP5), a member of the ubiquitin-specific proteases (USPs) family, functions by specifically removing ubiquitin chains from target proteins for stabilization and degrading unbound polyubiquitin chains to maint...
Treatment Continuity and Bone Marrow Suppression in Whole-Brain and Whole-Spinal Cord Radiotherapy for Medulloblastoma Patients [0.03%]
全脑及全脊髓放射治疗对髓母细胞瘤患者骨髓抑制的影响
Zongtai Li,Zhiyue Lin,Hui Liu et al.
Zongtai Li et al.
Background: This study investigated the factors influencing treatment continuity and bone marrow suppression in whole-brain and whole-spinal cord radiotherapy for medulloblastoma, providing a clinical reference for mitiga...
Serum Albumin as a Prognostic Biomarker for Febrile Neutropenia Outcome and Complications: A Prospective Observational Trial [0.03%]
血清白蛋白作为发热性中性粒细胞减少症预后生物标志物的预测价值：一项前瞻性观察试验
Jelena Dimitrijević,Marina Čalamać,Ognjen Đurmez et al.
Jelena Dimitrijević et al.
Background: Febrile neutropenia (FN) poses a significant challenge in cancer treatment, with a high incidence among patients undergoing standard therapies. Predicting FN complications and outcomes remains crucial for impr...
The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer [0.03%]
转移性激素敏感性前列腺癌的治疗格局日新月异
Eun-Mi Yu,Ishan Patel,Min Woo Hwang et al.
Eun-Mi Yu et al.
The management of metastatic hormone-sensitive prostate cancer (mHSPC) or castration-sensitive prostate cancer (mCSPC) has become increasingly complex with the tremendous progress that has been made in this space within the past few decades...
SNAI2 as a Prognostic Biomarker Based on Cancer-Associated Fibroblasts in Patients With Lung Adenocarcinoma [0.03%]
基于肺癌相关肌成纤维细胞的SNAI2预后生物标志物作用研究
Tian-Tian Li,Qing-Gang Hao,Zhao-Wei Teng et al.
Tian-Tian Li et al.
Background: Lung adenocarcinoma (LUAD) is a common type of malignant tumor with therapeutic challenges. Cancer-associated fibroblasts (CAFs) promote LUAD growth and metastasis, regulate the tumor immune response, and infl...
A Novel Porphyromonas gingivalis Infection-Related Inflammatory Response-Related Genes Signature Predicts the Prognosis of Esophageal Squamous Cell Carcinoma [0.03%]
牙龈卟啉单胞菌感染相关炎症反应基因谱预测食管鳞癌预后
Jinyu Kong,Yiwen Liu,Jian Wang et al.
Jinyu Kong et al.
Background: Our previous research showed that Porphyromonas gingivalis (P. gingivalis) infection can activate the inflammatory signaling pathway and promotes the malignancy development of esophageal squamous cell carcinom...
David Kw Leung,Ivan Ch Ko,Brian Wh Siu et al.
David Kw Leung et al.
Renal cell carcinoma (RCC) is the most common solid tumour of the kidney and accounts for 3% of all cancers. While immune checkpoint inhibitor (ICI)-based combination therapies have emerged as the first-line treatment for metastatic renal c...
Clinician Perspective on Once-Daily Zanubrutinib Dosing for B-Cell Malignancies at a Single Center [0.03%]
单中心医师对zanubrutinib每日一次给药治疗B细胞恶性肿瘤的视角
Mohit Narang,Courtney Horn,Edward Lee
Mohit Narang
Zanubrutinib, a next-generation, irreversible, highly potent, and selective Bruton tyrosine kinase inhibitor, is approved by the U.S. Food and Drug Administration to treat patients with B-cell malignancies in 2 dose regimens: 160 mg twice d...